Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome
Authors:
- 21 November 2006
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 86 (3) , 227-228
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab—monitoring of antiphospholipid and anti-GP antibodies: a case reportAnnals of Hematology, 2005
- Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpuraAmerican Journal of Hematology, 2005
- Long-term remission from life-threatening hypercoagulable state associated with lupus anticoagulant (LA) following rituximab therapyAmerican Journal of Hematology, 2005
- Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndromeRheumatology, 2004
- Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopeniaEuropean Journal of Internal Medicine, 2004
- The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpuraBritish Journal of Haematology, 2004
- The antiphospholipid syndrome as a model for B cell-induced autoimmune diseasesThrombosis Research, 2004
- Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort studyBlood, 2001
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- Thrombocytopenia in the antiphospholipid syndromeAnnals of the Rheumatic Diseases, 1997